Anavex Life Sciences Corp (AVXL) Q3 2025 Earnings Call Highlights: Strong Cash Position and ...
Debt: No debt reported.
Cash Utilization: $12.5 million used in operating activities during the quarter.
Runway: More than 3 years at the current adjusted cash utilization rate.
Research and Development Expenses: $10 million for the quarter, down from $11.8 million in the same quarter last year.
General and Administrative Expenses: $4.5 million for the quarter, up from $2.8 million in the same quarter last year.
Net Loss: $13.2 million for the quarter, or $0.16 per share.
Warning! GuruFocus has detected 1 Warning Sign with AVXL.
Release Date: August 12, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
Anavex Life Sciences Corp (NASDAQ:AVXL) presented promising open-label extension data for blarcamesine at the Alzheimer's Association International Conference, showing continued clinically meaningful benefits in early-stage Alzheimer's patients.
The company has a strong cash position of $101.2 million with no debt, providing a financial runway of over three years at the current cash utilization rate.
Blarcamesine demonstrated a favorable treatment duration to time saved ratio when benchmarked against other treatments like Leqembi and Kisunla.
Anavex Life Sciences Corp (NASDAQ:AVXL) is exploring the potential of blarcamesine for broader therapeutic applications, including mild to moderate Alzheimer's disease and other rare diseases.
The company is actively engaging with policymakers and exploring strategic partnerships to enhance commercialization efforts for blarcamesine in Europe and potentially other markets.
Negative Points
Research and development expenses remain high at $10 million for the quarter, with significant spending on manufacturing preparations and trial readiness.
The company reported a net loss of $13.2 million for the quarter, equating to a loss of $0.16 per share.
There is uncertainty regarding the timeline and outcome of the European Medicines Agency (EMA) review for blarcamesine, with feedback expected in the first quarter of next year.
The Parkinson's disease study has been delayed due to challenges in study design and the need to increase the chance of success.
Anavex Life Sciences Corp (NASDAQ:AVXL) faces competition from injectable treatments, and there is a need to emphasize the benefits of oral administration to achieve broader market penetration.
Q & A Highlights
Q: Could you explain the difference in the trajectory of patients in the 4-year open-label extension data for blarcamesine, particularly regarding the ADAS-Cog13 and ADCS-ADL readouts? A: Patients were initially randomized to receive either placebo or blarcamesine. Those who started on blarcamesine from day one showed better outcomes than those who began after the placebo phase. The ADAS-Cog13 is more sensitive to immediate changes, while ADCS-ADL is smoother in trajectory. The key takeaway is to start treatment early and maintain it without interruption for optimal benefits. (Christopher Missling, CEO)
Q: Are there plans for Alzheimer's prevention trials with blarcamesine? A: Yes, there are plans for a preventative trial based on preclinical work showing potential in preventing dementia onset in animals. However, executing such a long-term study requires more resources, so the focus is first on bringing the drug to market. (Christopher Missling, CEO)
Q: What are the strategic objectives of Anavex's engagement with policymakers and government relations? A: The goal is to raise awareness and emphasize the need for funding and attention to Alzheimer's disease. This involves educating policymakers about the unmet needs of patients with dementia and Alzheimer's, which is a common practice among companies. (Christopher Missling, CEO)
Q: What is the status of Anavex's pipeline, particularly regarding Parkinson's and Rett syndrome trials? A: Preparations are underway for manufacturing and trials in Parkinson's disease, Fragile X, and another rare disease. The Parkinson's trial design is being refined to increase the chance of success, while the Rett program is awaiting more clarity on Alzheimer's submissions before proceeding. (Christopher Missling, CEO)
Q: How does Anavex plan to commercialize blarcamesine if approved by the EMA? A: All options are open, including partnering with companies for marketing in Europe or going solo if it results in higher shareholder value. The decision will be based on what best serves shareholders. (Christopher Missling, CEO)
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Nagarro releases unaudited Q2 2025 results, posts 4.7% YoY revenue growth in constant currency and 14.2% increase in gross profit despite global macroeconomic challenges
MUNICH, Aug. 14, 2025 /CNW/ -- Nagarro, a global digital engineering leader, today presented its unaudited financial numbers for Q2 2025 and released its half-yearly financial report. In Q2 2025, revenue grew to €252.0 million, up 3.2% YoY from €244.1 million in Q2 2024. Constant currency YoY revenue growth for Q2 2025 was 4.7%. Organic YoY revenue growth for the quarter was 3.8% in constant currency, which translated to 2.4% organic YoY revenue growth in Euro terms. Gross profit grew to €83.7 million in Q2 2025 from €73.3 million in Q2 2024. Gross margin was 33.2% in Q2 2025, against 30.0% in Q2 2024. Despite excellent operational efficiency in Q1 and Q2 2025, Adjusted EBITDA was significantly impacted by the revaluation loss on inter-company loans from Nagarro SE and its cash holdings due to the weakening of the US dollar against the Euro. Across Q1 and Q2 2025, the total impact on Adjusted EBITDA of currency revaluation plus foreign exchange forward transactions was a negative €18.0 million. Consequently, Adjusted EBITDA for Q2 2025 was €30.5 million (12.1% of revenue), against €35.5 million (14.5% of revenue) in Q2 2024. EBITDA declined to €32.0 million in Q2 2025, from €32.8 million in Q2 2024. EBIT grew marginally to €23.4 million in Q2 2025, from €23.1 million in Q2 2024. Net profit declined to €8.3 million in Q2 2025 against €12.0 million in Q2 2024 mainly due to increase in income tax expense on account of withholding taxes on inter-company dividends remitted by downstream subsidiaries to their immediate holding companies. The number of clients doing more than €1 million in annual revenue in the last 12 months with Nagarro rose from 184 on June 30, 2024 to 188 on June 30, 2025. A dividend of €1.00 per share amounting to €12.6 million (13.1% of 2024 EBIT) has been declared during the Annual General Meeting held on June 30, 2025. H1 results Revenue grew to €498.9 million in H1 2025, up 3.4% YoY from €482.4 million in H1 2024. Constant currency revenue growth for H1 2025 was 3.6%. Organic YoY revenue growth for H1 2025 was 2.8% in constant currency, which translated to 2.6% organic YoY revenue growth in Euro terms. Gross profit grew to €159.3 million in H1 2025 from €146.9 million in H1 2024. Gross margin was 31.9% in H1 2025, against 30.5% in H1 2024. Adjusted EBITDA was €60.8 million (12.2% of revenue) in H1 2025, against €74.7 million (15.5% of revenue) in H1 2024. EBITDA declined to €65.0 million in H1 2025 from €68.8 million in H1 2024. EBIT declined to €47.5 million in H1 2025 from €49.7 million in H1 2024. Net profit declined to €19.6 million in H1 2025 against €28.6 million in H1 2024 mainly due to increase in income tax expense on account of withholding taxes on inter-company dividends remitted by downstream subsidiaries to their immediate holding companies. Operating cash inflow in H1 2025 declined to €26.1 million from €27.6 million in H1 2024, even while factoring utilization under the non-recourse factoring program was reduced by €8.5 million in H1 2025 from December 31, 2024. Days of sales outstanding, calculated based on the quarterly revenue and including both contract assets and trade receivables, has improved from 88 days on December 31, 2024 to 85 days on June 30, 2025. Nagarro's cash balance at the end of June 30, 2025 was €121.8 million as against €192.6 million at the end of December 31, 2024. Nagarro's loans and borrowings at the end of June 30, 2025, were €300.7 million as against €329.6 million at the end of December 31, 2024. The company reported 17,447 professionals as of June 30, 2025. The summarized table for the three-months period ended June 30, 2025 is as follows: Q2 2025Q2 2024Growth mEURmEUR Revenue252.0244.13.2% YoY4.7% YoY in constant currency Gross profit83.773.314.2% YoY Gross margin33.2 %30.0 % Adjusted EBITDA30.535.5Negative 14.1% YoY Adjusted EBITDA margin12.1 %14.5 % EBITDA32.032.8Negative 2.4% YoY EBIT23.423.11.3% YoY Net profit8.312.0Negative 30.8% YoYThe summarized table for the six-months period ended June 30, 2025 is as follows: H1 2025H1 2024Growth mEURmEUR Revenue498.9482.43.4% YoY3.6% YoY in constant currency Gross profit159.3146.98.4% YoY Gross margin31.9 %30.5 % Adjusted EBITDA60.874.7Negative 18.6% YoY Adjusted EBITDA margin12.2 %15.5 % EBITDA65.068.8Negative 5.5% YoY EBIT47.549.7Negative 4.4% YoY Net profit19.628.6Negative 31.5% YoYSupervisory Board committees The committees of Nagarro's Supervisory Board have been freshly reconstituted. Martin Enderle, Chair of the Supervisory Board, is also the Chair of the Nomination & Remuneration Committee. Until recently he was Chair of the Supervisory Board of Delivery Hero. Hans-Paul Buerkner, who was previously global CEO and Chairman of BCG, is the Chair of the Strategy Committee. Jack Clemons, who was global CEO of Bata and has been on various other boards, including being Chair of the Audit and Risk Committee of the Worldwide Fund for Nature (WWF), is Chair of the Audit Committee. Update on guidance On January 23, 2025, we had projected Nagarro's revenue for 2025 to be between €1,020 and €1,080 million, when calculated at the currency exchange rates then prevailing. We now expect Nagarro's revenue for 2025 to come near the lower end of that guidance. We targeted gross margin in the region of 30%, as compared to 30.4% in 2024. We hold to this expectation of gross margin. We targeted the Adjusted EBITDA margin to be between 14.5% and 15.5%, compared to 15.2% in 2024. Despite strong underlying operational performance of the company, the revaluation loss on inter-company loans and cash holdings because of the weakening of the US dollar against the Euro is currently expected to lead the Adjusted EBITDA margin to be between 13.5% and 14.5%. Nagarro SE will hold its analyst and investors meeting as a video call to discuss the half-yearly financial report 2025 on August 14, 2025, 1:00 pm CEST (4:00 am PT / 6:00 am CT / 7:00 am ET / 12:00 pm BST / 3:00 pm GST / 4:30 pm IST / 7:00 pm SGT / 8:00 pm JST). Nagarro SE will hold its retail investors call to discuss the half-yearly financial report 2025 on August 14, 2025, at 2:30 pm CEST (5:30 am PT / 7:30 am CT / 8:30 am ET / 1:30 pm BST / 4:30 pm GST / 6:00 pm IST / 8:30 pm SGT / 9:30 pm JST). To attend, please register in advance at About Nagarro Nagarro, a global digital engineering leader, helps clients become fluidic, innovative, digital-first companies and thus win in their markets. The company is distinguished by its entrepreneurial, agile, and global character, its CARING mindset, and its Fluidic Enterprise vision. Nagarro employs around 17,400 people in 39 countries. For more information, visit (FRA: NA9) (SDAX/TecDAX: DE000A3H2200) (ISIN: DE000A3H2200) (WKN: A3H220) For inquiries, please contact press@ Logo: View original content: SOURCE Nagarro View original content: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16 minutes ago
- Yahoo
Bitcoin price hits record high above $123,500 amid crypto rally
Bitcoin (BTC-USD) surged to a new all-time high above $123,500 (£90,984) in early Thursday trading, extending a week-long rally that has lifted the broader cryptocurrency market. Bitcoin briefly traded at $123,512 before easing back to around $121,700. The world's biggest cryptocurrency is now up more than 6% over the past week, breaking through its previous July peak of just over $120,000. Read more: Crypto live prices 'Bitcoin's latest rally reflects the blurring lines between crypto and traditional assets, happening faster than institutional adoption timelines predicted,' VOOI CEO and co-founder Will K said. 'While ETFs brought institutions into bitcoin, retail traders are returning to evolved decentralised platforms that have shed their clunky origins.' Ethereum (ETH-USD) outpaced bitcoin in percentage gains, jumping 28% over the past seven days to trade above $4,742, inching closer to its November 2021 record of $4,865. 'Ethereum's rally is being driven by strong ETF inflows, institutional accumulation, and a favourable macro backdrop after softer CPI data boosted rate-cut expectations,' Bitfinex head of derivatives Jag Kooner said. 'Traders have rotated back into risk, with bitcoin and ether both seeing renewed long positioning, while options data shows low implied volatility and a build-up in open interest, signalling that markets expect a sharp move ahead but are hedging downside risk.' The total cryptocurrency market capitalisation now stands at $4.23tn, up 1.9% on Thursday, according to CoinMarketCap data. The crypto rally comes as US equities closed higher on Wednesday, with the S&P 500 (^GSPC) and Nasdaq (^IXIC) hitting fresh record highs this week. The broader risk-on sentiment has spilled over into digital assets. Read more: One US law reshaped crypto overnight. Ripple explains why Bitcoin's surge has been underpinned by a friendlier regulatory climate in Washington. Earlier this month, US president Donald Trump signed an executive order directing federal banking regulators to scrap 'reputational risk' as a factor in supervision, a designation that had often led banks to cut ties with lawful crypto firms. The move, part of a broader rollback of restrictions critics dubbed 'Operation Choke Point 2.0,' has been coupled with the disbanding of the Justice Department's National Crypto Enforcement Team and new legislation to establish a federal framework for stablecoins. Industry leaders have said the shift is clearing a path for greater institutional participation in digital assets, adding momentum to bitcoin's rally. Read more: Why pension funds are buying bitcoin What is a spot bitcoin ETF and why has it sparked a crypto rally? How AI could change the internet
CNN
16 minutes ago
- CNN
NBA clears Boston Celtics' $6.1 billion sale to Bill Chisholm
A group headed by Bill Chisholm is set to take control of the Boston Celtics after the NBA Board of Governors unanimously approved the sale on Wednesday. The NBA wrote in a statement, 'The transaction is expected to close shortly.' The reported $6.1 billion valuation for the club makes it the second-largest sale price for a US sports franchise, behind the $10 billion valuation for the Los Angeles Lakers when Mark Walter purchased that team in June. Chisholm and his partners are buying at least 51 percent of the Celtics. The ownership stake will increase in 2028, according to the purchase contract, when Chisholm's group is scheduled to buy out the remaining minority shareholders at a $7.3 billion valuation. According to multiple media reports, Chisholm will take over as the Celtics' governor when the sale goes through. Outgoing owner Wyc Grousbeck is expected to serve as alternate governor and remain the CEO through 2028. Grousbeck will cede his role when he no longer has the required ownership stake of at least 15 percent. Chisholm, the co-founder and managing partner of the California-based private equity firm STG Partners, is a Massachusetts native and longtime Celtics fan. Grousbeck and the outgoing ownership group Boston Basketball Partners LLC purchased the Celtics for $360 million in 2002. During that group's tenure, the club won NBA titles in 2007-08 and 2023-24 – the latter representing Boston's league-record 18th championship.
